Label-Free Fluorescent Poly(amidoamine) Dendrimer for Traceable and Controlled Drug Delivery.

Wang, G; Fu, L; Walker, A; Chen, X; Lovejoy, DB; Hao, M; Lee, A; Chung, R; Rizos, H; Irvine, M; Zheng, M; Liu, X; Lu, Y; Shi, B

Label-Free Fluorescent Poly(amidoamine) Dendrimer for Traceable and Controlled Drug Delivery.

Wang, G Fu, L

Walker, A Chen, X Lovejoy, DB Hao, M Lee, A Chung, R Rizos, H Irvine, M Zheng, M Liu, X Lu, Y Shi, B

Permalink

Publisher:: AMER CHEMICAL SOC
Publication Type:: Journal Article
Citation:: Biomacromolecules, 2019, 20, (5), pp. 2148-2158
Issue Date:: 2019-05-13

Closed Access

	Filename	Description	Size
	acs.biomac.9b00494.pdf	Published version	5.4 MB	Adobe PDF	View/Open

Copyright Clearance Process

Recently Added
In Progress
Closed Access

This item is closed access and not available.

Full metadata record

Field	Value	Language
dc.contributor.author	Wang, G
dc.contributor.author	Fu, L https://orcid.org/0000-0001-8871-358X
dc.contributor.author	Walker, A
dc.contributor.author	Chen, X
dc.contributor.author	Lovejoy, DB
dc.contributor.author	Hao, M
dc.contributor.author	Lee, A
dc.contributor.author	Chung, R
dc.contributor.author	Rizos, H
dc.contributor.author	Irvine, M
dc.contributor.author	Zheng, M
dc.contributor.author	Liu, X
dc.contributor.author	Lu, Y
dc.contributor.author	Shi, B
dc.date.accessioned	2022-09-11T21:35:56Z
dc.date.available	2022-09-11T21:35:56Z
dc.date.issued	2019-05-13
dc.identifier.citation	Biomacromolecules, 2019, 20, (5), pp. 2148-2158
dc.identifier.issn	1525-7797
dc.identifier.issn	1526-4602
dc.identifier.uri	http://hdl.handle.net/10453/161690
dc.description.abstract	Poly(amidoamine) dendrimer (PAMAM) is well-known for its high efficiency as a drug delivery vehicle. However, the intrinsic cytotoxicity and lack of a detectable signal to facilitate tracking have impeded its practical applications. Herein, we have developed a novel label-free fluorescent and biocompatible PAMAM derivative by simple surface modification of PAMAM using acetaldehyde. The modified PAMAM possessed a strong green fluorescence, which was generated by the C=N bonds of the resulting Schiff Bases via n-π* transition, while the intrinsic cytotoxicity of PAMAM was simultaneously ameliorated. Through further PEGylation, the fluorescent PAMAM demonstrated excellent intracellular tracking in human melanoma SKMEL28 cells. In addition, our PEGylated fluorescent PAMAM derivative achieved enhanced loading and delivery efficiency of the anticancer drug doxorubicin (DOX) compared to the original PAMAM. Importantly, the accelerated kinetics of DOX-encapsulated fluorescent PAMAM nanocomposites in an acidic environment facilitated intracellular drug release, which demonstrated comparable cytotoxicity to that of the free-form doxorubicin hydrochloride (DOX·HCl) against melanoma cells. Overall, our label free fluorescent PAMAM derivative offers a new opportunity of traceable and controlled delivery for DOX and other drugs of potential clinical importance.
dc.format	Print-Electronic
dc.language	eng
dc.publisher	AMER CHEMICAL SOC
dc.relation.ispartof	Biomacromolecules
dc.relation.isbasedon	10.1021/acs.biomac.9b00494
dc.rights	info:eu-repo/semantics/closedAccess
dc.subject	03 Chemical Sciences, 06 Biological Sciences, 09 Engineering
dc.subject.classification	Polymers
dc.subject.mesh	Acetaldehyde
dc.subject.mesh	Antineoplastic Agents
dc.subject.mesh	Cell Line, Tumor
dc.subject.mesh	Dendrimers
dc.subject.mesh	Doxorubicin
dc.subject.mesh	Drug Carriers
dc.subject.mesh	Drug Liberation
dc.subject.mesh	Fluorescent Dyes
dc.subject.mesh	HEK293 Cells
dc.subject.mesh	Humans
dc.subject.mesh	Nanocomposites
dc.subject.mesh	Polyamines
dc.subject.mesh	Polyethylene Glycols
dc.subject.mesh	Schiff Bases
dc.subject.mesh	Cell Line, Tumor
dc.subject.mesh	Humans
dc.subject.mesh	Polyethylene Glycols
dc.subject.mesh	Acetaldehyde
dc.subject.mesh	Polyamines
dc.subject.mesh	Schiff Bases
dc.subject.mesh	Doxorubicin
dc.subject.mesh	Antineoplastic Agents
dc.subject.mesh	Drug Carriers
dc.subject.mesh	Fluorescent Dyes
dc.subject.mesh	Dendrimers
dc.subject.mesh	Nanocomposites
dc.subject.mesh	HEK293 Cells
dc.subject.mesh	Drug Liberation
dc.title	Label-Free Fluorescent Poly(amidoamine) Dendrimer for Traceable and Controlled Drug Delivery.
dc.type	Journal Article
utslib.citation.volume	20
utslib.location.activity	United States
utslib.for	03 Chemical Sciences
utslib.for	06 Biological Sciences
utslib.for	09 Engineering
pubs.organisational-group	/University of Technology Sydney
pubs.organisational-group	/University of Technology Sydney/Faculty of Science
pubs.organisational-group	/University of Technology Sydney/Faculty of Science/School of Mathematical and Physical Sciences
utslib.copyright.status	closed_access	*
dc.date.updated	2022-09-11T21:35:00Z
pubs.issue	5
pubs.publication-status	Published
pubs.volume	20
utslib.citation.issue	5

Abstract:

Poly(amidoamine) dendrimer (PAMAM) is well-known for its high efficiency as a drug delivery vehicle. However, the intrinsic cytotoxicity and lack of a detectable signal to facilitate tracking have impeded its practical applications. Herein, we have developed a novel label-free fluorescent and biocompatible PAMAM derivative by simple surface modification of PAMAM using acetaldehyde. The modified PAMAM possessed a strong green fluorescence, which was generated by the C=N bonds of the resulting Schiff Bases via n-π* transition, while the intrinsic cytotoxicity of PAMAM was simultaneously ameliorated. Through further PEGylation, the fluorescent PAMAM demonstrated excellent intracellular tracking in human melanoma SKMEL28 cells. In addition, our PEGylated fluorescent PAMAM derivative achieved enhanced loading and delivery efficiency of the anticancer drug doxorubicin (DOX) compared to the original PAMAM. Importantly, the accelerated kinetics of DOX-encapsulated fluorescent PAMAM nanocomposites in an acidic environment facilitated intracellular drug release, which demonstrated comparable cytotoxicity to that of the free-form doxorubicin hydrochloride (DOX·HCl) against melanoma cells. Overall, our label free fluorescent PAMAM derivative offers a new opportunity of traceable and controlled delivery for DOX and other drugs of potential clinical importance.

Please use this identifier to cite or link to this item:

http://hdl.handle.net/10453/161690